Cother Hajat
Research Subjects
Cother Hajat has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Emma Stein
3 shared publications- Riccardo Polosa
Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
3 shared publications Derek Yach
Vitality Group, Chicago, Illinois, USA
2 shared publications- Enza Cestone
R&D Department, Complife Italia S.r.l., 27028 San Martino Siccomario, PV, Italy
2 shared publications - Federica Cascella
Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy
2 shared publications - Giacomo Santus
ROELMI Holding, 20020 Solaro, MI, Italy
2 shared publications
Latest Publications
- Open Access
Skin Antiaging and Skin Health Benefits of Probiotic Intake Combined with Topical Ectoin and Sodium Hyaluronate: A Randomized, Double-Blind, Placebo-Controlled Trial
Well-aging strategies include the use of both oral and topic products to nourish the skin from the inside out. A clinical–instrumental study was conducted on 96 Caucasian subjects with mild-to-moderate facial aging to demonstrate the efficacy of probiotic (Lactobacillus plantarum PBS067, Lactobacillus reuteri PBS072, and Lactobacillus rhamnosus LRH020) intake combined with topical ectoin and sodium hyaluronate. The skin sebum content, hydration and moisturization, profilometry (wrinkle depth and skin smoothness), TEWL, elasticity (R0 and R2 parameters), radiance, and pores (size and impurities) were measured after 4 and 8 weeks of product use. These parameters were also integrated through a self-assessment questionnaire to align the measured and the perceived efficacy. One hour after serum application, the wrinkle depth was reduced by 9.2%, while skin hydration increased by 16.6% and skin radiance by 19.1% following cream application. After 4 and 8 weeks of use, both the oral and topical products were shown to respect the skin’s hydrolipid film, effectively improve skin parameters associated with aging, and detoxify the skin from impurities. The mechanism behind these improvements was linked to an enhancement of the skin microbiome. Our findings clearly demonstrate the efficacy of probiotic intake combined with topical ectoin and sodium hyaluronate in enhancing skin health and mitigating the signs of skin aging.
Open AccessSkin Antiaging and Skin Health Benefits of Probiotic Intake Combined with Topical Ectoin and Sodium Hyaluronate: A Randomized, Double-Blind, Placebo-Controlled Trial
Well-aging strategies include the use of both oral and topic products to nourish the skin from the inside out. A clinical–instrumental study was conducted on 96 Caucasian subjects with mild-to-moderate facial aging to demonstrate the efficacy of probiotic (Lactobacillus plantarum PBS067, Lactobacillus reuteri PBS072, and Lactobacillus rhamnosus LRH020) intake combined with topical ectoin and sodium hyaluronate. The skin sebum content, hydration and moisturization, profilometry (wrinkle depth and skin smoothness), TEWL, elasticity (R0 and R2 parameters), radiance, and pores (size and impurities) were measured after 4 and 8 weeks of product use. These parameters were also integrated through a self-assessment questionnaire to align the measured and the perceived efficacy. One hour after serum application, the wrinkle depth was reduced by 9.2%, while skin hydration increased by 16.6% and skin radiance by 19.1% following cream application. After 4 and 8 weeks of use, both the oral and topical products were shown to respect the skin’s hydrolipid film, effectively improve skin parameters associated with aging, and detoxify the skin from impurities. The mechanism behind these improvements was linked to an enhancement of the skin microbiome. Our findings clearly demonstrate the efficacy of probiotic intake combined with topical ectoin and sodium hyaluronate in enhancing skin health and mitigating the signs of skin aging.
- Open Access
- 6 January 2025
- Published by MDPI AG in Preprints.org
Skin Antiaging and Skin Health Benefits of Probiotics Intake Combined with Topical Ectoin and Sodium Hyaluronate: A Randomized, Double-Blind, Placebo-Controlled Trial
Well-aging strategies include the use of both oral and topic products to nourish the skin from the inside out. A clinical-instrumental study was conducted on 96 subjects with mild to moderate facial aging to demonstrate the efficacy of probiotics (Lactobacillus plantarum PBS067, Lactobacillus reuteri PBS072 and Lactobacillus rhamnosus LRH020) intake combined with topical ectoin and sodium hyaluronate. The skin sebum content, hydration and moisturization, profilometry (wrinkle depth and skin smoothness), TEWL, elasticity (R0 and R2 parameters), radiance, and pores (size and impurities) were measured after 4 and 8 weeks of products use. These parameters were also integrated by a self-assessment questionnaire to align the measured and the perceived efficacy. One hour after serum application, wrinkle depth was reduced by 9.2%, while skin hydration increased by 16.6% and skin radiance by 19.1% following cream application. After 4 and 8 weeks of use, both the oral and topical products were shown to respect the skin's hydrolipid film, effectively improve skin parameters associated with aging, and detoxify the skin from impurities. The mechanism behind these improvements was linked to an enhancement of the skin microbiome. Our findings clearly demonstrate the efficacy of probiotic intake combined with topical ectoin and sodium hyaluronate in enhancing skin health and mitigating signs of skin aging.
- 6 January 2025
- Published by MDPI AG in Preprints.org
Open AccessSkin Antiaging and Skin Health Benefits of Probiotics Intake Combined with Topical Ectoin and Sodium Hyaluronate: A Randomized, Double-Blind, Placebo-Controlled Trial
Well-aging strategies include the use of both oral and topic products to nourish the skin from the inside out. A clinical-instrumental study was conducted on 96 subjects with mild to moderate facial aging to demonstrate the efficacy of probiotics (Lactobacillus plantarum PBS067, Lactobacillus reuteri PBS072 and Lactobacillus rhamnosus LRH020) intake combined with topical ectoin and sodium hyaluronate. The skin sebum content, hydration and moisturization, profilometry (wrinkle depth and skin smoothness), TEWL, elasticity (R0 and R2 parameters), radiance, and pores (size and impurities) were measured after 4 and 8 weeks of products use. These parameters were also integrated by a self-assessment questionnaire to align the measured and the perceived efficacy. One hour after serum application, wrinkle depth was reduced by 9.2%, while skin hydration increased by 16.6% and skin radiance by 19.1% following cream application. After 4 and 8 weeks of use, both the oral and topical products were shown to respect the skin's hydrolipid film, effectively improve skin parameters associated with aging, and detoxify the skin from impurities. The mechanism behind these improvements was linked to an enhancement of the skin microbiome. Our findings clearly demonstrate the efficacy of probiotic intake combined with topical ectoin and sodium hyaluronate in enhancing skin health and mitigating signs of skin aging.
- Open Access
- 12 July 2023
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 10, 1196475
Halal cultivated meat: an untapped opportunity
The global Halal food market is forecast to reach US$1.67 trillion by 2025, growing to meet the dietary demands of a rapidly increasing Muslim population, set to comprise 30% of the global population by mid-century. Meat consumption levels are increasing in many Muslim countries, with important implications for health and environmental sustainability. Alt protein products are currently being manufactured and positioned as one possible solution to reduce the environmental impact of meat consumption, yet, little is currently known about the Halal status of these products, nor the extent to which they appeal to Muslim consumers in emerging markets in Asia and Africa. Here, we explore key considerations regarding the acceptability of alt protein products for Muslim consumers, explore Halal certification requirements in the context of cultivated meat, and examine some unique beliefs within the Islamic faith that may support, as well as impede, widespread adoption of alt protein among the 2.8 billion Muslims of the future.
- 12 July 2023
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 10, 1196475
Open AccessHalal cultivated meat: an untapped opportunity
The global Halal food market is forecast to reach US$1.67 trillion by 2025, growing to meet the dietary demands of a rapidly increasing Muslim population, set to comprise 30% of the global population by mid-century. Meat consumption levels are increasing in many Muslim countries, with important implications for health and environmental sustainability. Alt protein products are currently being manufactured and positioned as one possible solution to reduce the environmental impact of meat consumption, yet, little is currently known about the Halal status of these products, nor the extent to which they appeal to Muslim consumers in emerging markets in Asia and Africa. Here, we explore key considerations regarding the acceptability of alt protein products for Muslim consumers, explore Halal certification requirements in the context of cultivated meat, and examine some unique beliefs within the Islamic faith that may support, as well as impede, widespread adoption of alt protein among the 2.8 billion Muslims of the future.
- Open Access
- 11 January 2022
- Published by Center for Open Science in OSF Preprints
The Future of Food to Tackle Climate and Health – Reflections from COP26
A shift in how we obtain protein from our diets, away from intensive farming and fishing, towards cleaner sources, be they animal or plant-based, will form an essential part of the solution to achieving the pledges formalised following COP26. This can be achieved through many different approaches including reduction, substitution, reducing the frequency of consumption, blending into hybrid products, and without the necessity of a complete eschewal of animal-based products. The new paradigm of ‘planetary health’, which focuses on the interdependence of human health, animal health and environmental health, will greatly facilitate meeting the ambitious and near-term targets set. This commentary discusses these issues in depth, with a focus on solutions to promote both planetary and human health in unison.
- 11 January 2022
- Published by Center for Open Science in OSF Preprints
Open AccessThe Future of Food to Tackle Climate and Health – Reflections from COP26
A shift in how we obtain protein from our diets, away from intensive farming and fishing, towards cleaner sources, be they animal or plant-based, will form an essential part of the solution to achieving the pledges formalised following COP26. This can be achieved through many different approaches including reduction, substitution, reducing the frequency of consumption, blending into hybrid products, and without the necessity of a complete eschewal of animal-based products. The new paradigm of ‘planetary health’, which focuses on the interdependence of human health, animal health and environmental health, will greatly facilitate meeting the ambitious and near-term targets set. This commentary discusses these issues in depth, with a focus on solutions to promote both planetary and human health in unison.
- Open Access
- 4 December 2021
- Published by Springer Nature in Harm Reduction Journal
- Vol. 18 (1) , 1-21
The health impact of smokeless tobacco products: a systematic review
Introduction: The objective was to systematically review studies on health outcomes from smokeless tobacco (SLT) products.Methods: We analysed published literature on the health outcomes from SLT use between 01/01/2015 to 01/02/2020, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol using PubMed, Embase, Scopus, and Google Scholar.Results: Of 53 studies included, six were global, 32 from Asia, Middle East and Africa (AMEA), nine from USA and six from Europe. ‘Poor’-rated studies predominated (23;43%), in particular, for global (4;66%) and AMEA (16;50%). Health outcomes differed between SLT-products and regions; those in AMEA were associated with higher mortality (overall, cancer, Coronary heart disease (CHD), respiratory but not cardiovascular disease (CVD)), and morbidity (CVD, oral and head and neck cancers), with odds ratios up to 38.7. European studies showed no excess mortality (overall, CVD, from cancers) or morbidity (ischemic heart disease (IHD), stroke, oral, head and neck, pancreatic or colon cancers) from several meta-analyses; single studies reported elevated risk of rectal cancer and respiratory disorders. Pooled study data showed protection against developing Parkinson’s disease. US studies showed mixed results for mortality (raised overall, CHD, cancer and smoking-related cancer mortality; no excess risk of respiratory or CVD mortality). Morbidity outcomes were also mixed, with some evidence of increased IHD, stroke and cancer risk (oral, head and neck). No studies reported on switching from cigarettes to SLT-products.Conclusion: Our review demonstrates stark differences between different SLT-products in different regions, ranging from zero harm from European snus to greatly increased health risks in AMEA. The literature on the safety profile for SLT-products for harm reduction is incomplete and potentially misinforming policy and regulation.
- 4 December 2021
- Published by Springer Nature in Harm Reduction Journal
- Vol. 18 (1) , 1-21
Open AccessThe health impact of smokeless tobacco products: a systematic review
Introduction: The objective was to systematically review studies on health outcomes from smokeless tobacco (SLT) products.Methods: We analysed published literature on the health outcomes from SLT use between 01/01/2015 to 01/02/2020, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol using PubMed, Embase, Scopus, and Google Scholar.Results: Of 53 studies included, six were global, 32 from Asia, Middle East and Africa (AMEA), nine from USA and six from Europe. ‘Poor’-rated studies predominated (23;43%), in particular, for global (4;66%) and AMEA (16;50%). Health outcomes differed between SLT-products and regions; those in AMEA were associated with higher mortality (overall, cancer, Coronary heart disease (CHD), respiratory but not cardiovascular disease (CVD)), and morbidity (CVD, oral and head and neck cancers), with odds ratios up to 38.7. European studies showed no excess mortality (overall, CVD, from cancers) or morbidity (ischemic heart disease (IHD), stroke, oral, head and neck, pancreatic or colon cancers) from several meta-analyses; single studies reported elevated risk of rectal cancer and respiratory disorders. Pooled study data showed protection against developing Parkinson’s disease. US studies showed mixed results for mortality (raised overall, CHD, cancer and smoking-related cancer mortality; no excess risk of respiratory or CVD mortality). Morbidity outcomes were also mixed, with some evidence of increased IHD, stroke and cancer risk (oral, head and neck). No studies reported on switching from cigarettes to SLT-products.Conclusion: Our review demonstrates stark differences between different SLT-products in different regions, ranging from zero harm from European snus to greatly increased health risks in AMEA. The literature on the safety profile for SLT-products for harm reduction is incomplete and potentially misinforming policy and regulation.
- Open Access
- 14 June 2021
- Published by Qeios Ltd in Qeios Preprints
Critical analysis of common methodology flaws in e-cigarette surveys
The prevalence of vaping, also known as using e-cigarettes, vapes, vape pens, or electronic nicotine delivery systems (ENDS) has prompted a demand for reliable, evidence-based research.1 However, published literature on the topic of vaping is often unreliable, characterized by serious flaws and a failure to adhere to accepted scientific methodologies. In this narrative review, we analyze 24 popular vaping studies, published in medical journals, that purport to evaluate the association of vaping and smoking initiation, smoking cessation or health outcomes. We analyzed these studies to identify the questions they claimed to address, stated methods, manner of implementation, discussions, and stated conclusions. After critical appraisal, we noted a multiplicity of flaws in these studies, and identified patterns as to the nature of such flaws. Many studies lacked a clear hypothesis statement: to the extent that a hypothesis could be inferred, the methods were not tailored to address the question of interest. Moreover, main outcome measures were poorly identified, and data analysis was further complicated by failure to control for confounding factors. The body of literature on “gateway” theory for the initiation of smoking was particularly unreliable. Overall, the results and discussion contained numerous unreliable assertions due to poor methods, including data collection that lacked relevance, and assertions that were unfounded. Many researchers claimed to find a causal association while not supporting such findings with meaningful data: the discussions and conclusions of such studies were therefore misleading. Herein, we identify the common flaws in the study design, methodology, and implementation found in published vaping studies. Our aim is to prompt future researchers to adhere to scientific methods to produce more reliable findings and conclusions in the field of vaping research.
- 14 June 2021
- Published by Qeios Ltd in Qeios Preprints
Open AccessCritical analysis of common methodology flaws in e-cigarette surveys
The prevalence of vaping, also known as using e-cigarettes, vapes, vape pens, or electronic nicotine delivery systems (ENDS) has prompted a demand for reliable, evidence-based research.1 However, published literature on the topic of vaping is often unreliable, characterized by serious flaws and a failure to adhere to accepted scientific methodologies. In this narrative review, we analyze 24 popular vaping studies, published in medical journals, that purport to evaluate the association of vaping and smoking initiation, smoking cessation or health outcomes. We analyzed these studies to identify the questions they claimed to address, stated methods, manner of implementation, discussions, and stated conclusions. After critical appraisal, we noted a multiplicity of flaws in these studies, and identified patterns as to the nature of such flaws. Many studies lacked a clear hypothesis statement: to the extent that a hypothesis could be inferred, the methods were not tailored to address the question of interest. Moreover, main outcome measures were poorly identified, and data analysis was further complicated by failure to control for confounding factors. The body of literature on “gateway” theory for the initiation of smoking was particularly unreliable. Overall, the results and discussion contained numerous unreliable assertions due to poor methods, including data collection that lacked relevance, and assertions that were unfounded. Many researchers claimed to find a causal association while not supporting such findings with meaningful data: the discussions and conclusions of such studies were therefore misleading. Herein, we identify the common flaws in the study design, methodology, and implementation found in published vaping studies. Our aim is to prompt future researchers to adhere to scientific methods to produce more reliable findings and conclusions in the field of vaping research.
- Open Access
- 21 February 2021
- Published by Center for Open Science in OSF Preprints
Communication of Risk in Covid-19: An Urgent Need for Clarity
The Covid-19 pandemic has resulted in an unprecedented spotlight on health risks. This article discusses how such risks have been communicated to the public, arguing the approaches used may have inflated perceptions of risk amongst younger and disease-free individuals. This has led to undue anxiety and had a deleterious effect on other health behaviours, including sleep and exercise. We advise that more conventional public health messaging approaches would have been useful - deploying clear, non-jargon language, keeping advice consistent and presenting a combination of absolute health risks and comparisons with other everyday risks. This may have facilitated more accurate understanding of risk levels in different population segments. The evidence-base on effective ways to communicate to encourage health-seeking behaviour change – such as emphasizing the benefits of compliance to recommendations rather than the risks of non-compliance and highlighting the social impacts of Covid-19 preventative measures – must be more effectively leveraged in future to support risk mitigation efforts and implementation of vaccines during their forthcoming rollout.
- 21 February 2021
- Published by Center for Open Science in OSF Preprints
Open AccessCommunication of Risk in Covid-19: An Urgent Need for Clarity
The Covid-19 pandemic has resulted in an unprecedented spotlight on health risks. This article discusses how such risks have been communicated to the public, arguing the approaches used may have inflated perceptions of risk amongst younger and disease-free individuals. This has led to undue anxiety and had a deleterious effect on other health behaviours, including sleep and exercise. We advise that more conventional public health messaging approaches would have been useful - deploying clear, non-jargon language, keeping advice consistent and presenting a combination of absolute health risks and comparisons with other everyday risks. This may have facilitated more accurate understanding of risk levels in different population segments. The evidence-base on effective ways to communicate to encourage health-seeking behaviour change – such as emphasizing the benefits of compliance to recommendations rather than the risks of non-compliance and highlighting the social impacts of Covid-19 preventative measures – must be more effectively leveraged in future to support risk mitigation efforts and implementation of vaccines during their forthcoming rollout.
- Open Access
- 21 January 2021
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 8
Clustering and Healthcare Costs With Multiple Chronic Conditions in a US Study
Objective: To investigate healthcare costs and contributors to costs for multiple chronic conditions (MCCs), common clusters of conditions and their impact on cost and utilization.Methods: This was a cross-sectional analysis of US financial claims data representative of the US population, including Medicare, Medicaid, and Commercial insurance claims in 2015. Outcome measures included healthcare costs and contributors; ranking of clusters of conditions according to frequency, strength of association and unsupervised (k-means) analysis; the impact of clustering on costs and contributors to costs.Results: Of 1,878,951 patients, 931,045(49.6%) had MCCs, 56.5% weighted to the US population. Mean age was 53.0 years (SD16.7); 393,121(42.20%) were male. Mean annual healthcare spending was $12,601, ranging from $4,385 (2 conditions) to $33,874 (11 conditions), with spending increasing by 22-fold for inpatient services, 6-fold for outpatient services, 4.5-fold for generic drugs, and 4.2-fold for branded drugs. Cluster ranking using the 3 methodologies yielded similar results: highest ranked clusters included metabolic syndrome (12.2% of US insured patients), age related diseases (7.7%), renal failure (5.6%), respiratory disorders (4.5%), cardiovascular disease(CVD) (4.3%), cancers (4.1–4.3%), mental health-related clusters (1.0–1.5%), and HIV/AIDS (0.2%). Highest spending was in HIV/AIDS clusters ($48,293), mental health-related clusters ($38,952–$40,637), renal disease ($38,551), and CVD ($37,155); with 89.9% of spending on outpatient and inpatient care combined, and 10.1% on medication.Conclusion and Relevance: Over 57% of insured patients in the US may have MCCs. MCC Clustering is frequent and is associated with healthcare utilization. The findings favor health system redesign toward a multiple condition approach for clusters of chronic conditions, alongside other cost-containment measures for MCCs.
- 21 January 2021
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 8
Open AccessClustering and Healthcare Costs With Multiple Chronic Conditions in a US Study
Objective: To investigate healthcare costs and contributors to costs for multiple chronic conditions (MCCs), common clusters of conditions and their impact on cost and utilization.Methods: This was a cross-sectional analysis of US financial claims data representative of the US population, including Medicare, Medicaid, and Commercial insurance claims in 2015. Outcome measures included healthcare costs and contributors; ranking of clusters of conditions according to frequency, strength of association and unsupervised (k-means) analysis; the impact of clustering on costs and contributors to costs.Results: Of 1,878,951 patients, 931,045(49.6%) had MCCs, 56.5% weighted to the US population. Mean age was 53.0 years (SD16.7); 393,121(42.20%) were male. Mean annual healthcare spending was $12,601, ranging from $4,385 (2 conditions) to $33,874 (11 conditions), with spending increasing by 22-fold for inpatient services, 6-fold for outpatient services, 4.5-fold for generic drugs, and 4.2-fold for branded drugs. Cluster ranking using the 3 methodologies yielded similar results: highest ranked clusters included metabolic syndrome (12.2% of US insured patients), age related diseases (7.7%), renal failure (5.6%), respiratory disorders (4.5%), cardiovascular disease(CVD) (4.3%), cancers (4.1–4.3%), mental health-related clusters (1.0–1.5%), and HIV/AIDS (0.2%). Highest spending was in HIV/AIDS clusters ($48,293), mental health-related clusters ($38,952–$40,637), renal disease ($38,551), and CVD ($37,155); with 89.9% of spending on outpatient and inpatient care combined, and 10.1% on medication.Conclusion and Relevance: Over 57% of insured patients in the US may have MCCs. MCC Clustering is frequent and is associated with healthcare utilization. The findings favor health system redesign toward a multiple condition approach for clusters of chronic conditions, alongside other cost-containment measures for MCCs.
- Open Access
- 20 January 2021
- Published by Center for Open Science in OSF Preprints
The Health Impact of Smokeless Tobacco Products: A Systematic Review
IntroductionThe objective was to systematically review studies reporting on health outcomes from smokeless tobacco (SLT) products.MethodsWe included published literature on the health impact of SLT from 01/01/2015 until 01/02/2020 following the PRISMA protocol using PubMed, Embase, Scopus and Google Scholar. ResultsOf 321 studies identified, 53 met eligibility criteria; 23(43%) were rated as poor, 21(39%) fair and 9(17%) as good. Health outcomes differed starkly between SLT products and global regions. SLT products in Asia, Middle East and Africa were associated with higher mortality (overall, cancer, CHD, respiratory but not CVD), and morbidity (CVD, oral and head and neck cancers), with odds ratios as high as 39 (shammah use). European studies showed no excess mortality (overall, CVD, from cancers) or morbidity (IHD, stroke, oral, head and neck, pancreatic or colon cancers) from several meta-analyses but single studies reporting elevated risk of rectal cancer and respiratory disorders. Pooled studies showed a protective effect against developing Parkinson’s disease. US studies showed mixed results for mortality (raised overall, CHD, cancer and smoking-related cancer mortality; no excess risk of respiratory or CVD mortality). Morbidity outcomes were also mixed, with some evidence of increased IHD, stroke and cancer risk (oral, head and neck). No studies reported on the health impact of switching from cigarettes to SLT products. ConclusionOur review has demonstrated stark differences between different SLT products in different regions on health impact, ranging from no harm from European snus to greatly increased health risks from SLT products used in Asia, Middle East and Africa. The literature on the impact of SLT products for harm reduction is incomplete and potentially misinforming policy and regulation.
- 20 January 2021
- Published by Center for Open Science in OSF Preprints
Open AccessThe Health Impact of Smokeless Tobacco Products: A Systematic Review
IntroductionThe objective was to systematically review studies reporting on health outcomes from smokeless tobacco (SLT) products.MethodsWe included published literature on the health impact of SLT from 01/01/2015 until 01/02/2020 following the PRISMA protocol using PubMed, Embase, Scopus and Google Scholar. ResultsOf 321 studies identified, 53 met eligibility criteria; 23(43%) were rated as poor, 21(39%) fair and 9(17%) as good. Health outcomes differed starkly between SLT products and global regions. SLT products in Asia, Middle East and Africa were associated with higher mortality (overall, cancer, CHD, respiratory but not CVD), and morbidity (CVD, oral and head and neck cancers), with odds ratios as high as 39 (shammah use). European studies showed no excess mortality (overall, CVD, from cancers) or morbidity (IHD, stroke, oral, head and neck, pancreatic or colon cancers) from several meta-analyses but single studies reporting elevated risk of rectal cancer and respiratory disorders. Pooled studies showed a protective effect against developing Parkinson’s disease. US studies showed mixed results for mortality (raised overall, CHD, cancer and smoking-related cancer mortality; no excess risk of respiratory or CVD mortality). Morbidity outcomes were also mixed, with some evidence of increased IHD, stroke and cancer risk (oral, head and neck). No studies reported on the health impact of switching from cigarettes to SLT products. ConclusionOur review has demonstrated stark differences between different SLT products in different regions on health impact, ranging from no harm from European snus to greatly increased health risks from SLT products used in Asia, Middle East and Africa. The literature on the impact of SLT products for harm reduction is incomplete and potentially misinforming policy and regulation.
- Open Access
The Health Impact of Electronic Nicotine Delivery Systems: A Systematic Review
Introduction: The objective of this systematic review was to identify, report and critically appraise studies that have reported health outcomes from use of ENDS. Methods: We conducted a systematic review of all published literature on the health impact of ENDS products from 1 st January 2015 until February 1, 2020, following the PRISMA protocol, including across the databases, PubMed, Embase, Scopus and Google Scholar. Medical subject headings were used in the execution of PubMed searches. A category for the level of evidence was assigned blindly using the Centres for Evidence Based Medicine framework. A similar approach was adopted to evaluate methodological quality of each study utilizing the National Institutes for Health (NIH) Quality Assessment Tools. Results: The database search identified 755 studies and a further 265 were identified from other sources and reference reviews of which 37 studies met the eligibility criteria. The majority of studies were of low strength for levels of evidence including 24 (65%) cross-sectional, 1(2.7%) case-control and six (16%) case studies. There were four (11%) cohort studies and only one (2.7%) RCT. There was only one (2.7%) meta-analysis or pooled study of observational study designs; there were no pooled results of randomized controlled trials. Of 37 studies, eight (22%) studies reported on benefits, two (2%) studies were neutral, reporting on both harm and benefits, the remaining 27 (73%) reported only on harms. The quality ratings were poor (20, 54%), fair (9, 24%) and good (8, 22%). In our review ENDS use has not been shown to be causative for any CVD outcomes and has been shown to be beneficial for hypertensive patients. Switching from cigarettes to e-cigarettes resulted in reduced exacerbations of COPD, with no evidence of long-term deterioration in lung function. There was a suggestion of short-term reductions in respiratory function in asthmatics, but no increased risk of asthma in ENDS users who were never smokers. Mental Health, cancer and mortality have not been adequately studied to form any consensus with regards to health outcomes from ENDS use. Conclusion: Our review suggests that the majority of studies on the use of ENDS products reported on negative health impacts with few reporting on health outcomes from switching from cigarettes to e-cigarettes. The strength of evidence and quality of the published studies overall is poor. Our review has demonstrated that ENDS use is not causative for any harmful CVD outcomes and may be beneficial for hypertensive patients. Switching from cigarettes to e-cigarettes resulted in reduced exacerbations of COPD, with no evidence of increased risk of asthma, long-term respiratory harm or deterioration in lung function. Other health outcomes such as mental health, cancer and mortality have not been adequately studied to form a consensus. However, the findings of our review did not negate the consensus held by many that ENDS use is safer than the risks posed from smoking cigarettes. Overall, our review found the research on ENDS use is not yet adequate to provide quantitative estimates about health risks. Consequently, the current body of evidence is inadequate for informing policy around tobacco harm reduction.
Open AccessThe Health Impact of Electronic Nicotine Delivery Systems: A Systematic Review
Introduction: The objective of this systematic review was to identify, report and critically appraise studies that have reported health outcomes from use of ENDS. Methods: We conducted a systematic review of all published literature on the health impact of ENDS products from 1 st January 2015 until February 1, 2020, following the PRISMA protocol, including across the databases, PubMed, Embase, Scopus and Google Scholar. Medical subject headings were used in the execution of PubMed searches. A category for the level of evidence was assigned blindly using the Centres for Evidence Based Medicine framework. A similar approach was adopted to evaluate methodological quality of each study utilizing the National Institutes for Health (NIH) Quality Assessment Tools. Results: The database search identified 755 studies and a further 265 were identified from other sources and reference reviews of which 37 studies met the eligibility criteria. The majority of studies were of low strength for levels of evidence including 24 (65%) cross-sectional, 1(2.7%) case-control and six (16%) case studies. There were four (11%) cohort studies and only one (2.7%) RCT. There was only one (2.7%) meta-analysis or pooled study of observational study designs; there were no pooled results of randomized controlled trials. Of 37 studies, eight (22%) studies reported on benefits, two (2%) studies were neutral, reporting on both harm and benefits, the remaining 27 (73%) reported only on harms. The quality ratings were poor (20, 54%), fair (9, 24%) and good (8, 22%). In our review ENDS use has not been shown to be causative for any CVD outcomes and has been shown to be beneficial for hypertensive patients. Switching from cigarettes to e-cigarettes resulted in reduced exacerbations of COPD, with no evidence of long-term deterioration in lung function. There was a suggestion of short-term reductions in respiratory function in asthmatics, but no increased risk of asthma in ENDS users who were never smokers. Mental Health, cancer and mortality have not been adequately studied to form any consensus with regards to health outcomes from ENDS use. Conclusion: Our review suggests that the majority of studies on the use of ENDS products reported on negative health impacts with few reporting on health outcomes from switching from cigarettes to e-cigarettes. The strength of evidence and quality of the published studies overall is poor. Our review has demonstrated that ENDS use is not causative for any harmful CVD outcomes and may be beneficial for hypertensive patients. Switching from cigarettes to e-cigarettes resulted in reduced exacerbations of COPD, with no evidence of increased risk of asthma, long-term respiratory harm or deterioration in lung function. Other health outcomes such as mental health, cancer and mortality have not been adequately studied to form a consensus. However, the findings of our review did not negate the consensus held by many that ENDS use is safer than the risks posed from smoking cigarettes. Overall, our review found the research on ENDS use is not yet adequate to provide quantitative estimates about health risks. Consequently, the current body of evidence is inadequate for informing policy around tobacco harm reduction.